<DOC>
	<DOCNO>NCT02011321</DOCNO>
	<brief_summary>Vasospasm occur frequently aneurysmal subarachnoid hemorrhage lead stroke . The investigator investigate infusion novel drug , clevidipine , decrease vasospasm infusion post infusion period use transcranial doppler monitoring patient subarachnoid hemorrhage moderate severity vasospasm</brief_summary>
	<brief_title>Clevidipine Vasospasm After Subarachnoid Hemorrhage ( SAH )</brief_title>
	<detailed_description>Cerebral vasospasm aneurysmal subarachnoid hemorrhage ( SAH ) major cause morbidity mortality day secure aneurysm due development cerebral ischemia stroke . Vasospasm detect measure blood flow velocity cerebral circulation via daily Transcranial Dopplers ( TCD ) . There effective treatment except per o calcium channel blocker ( nimodipine ) keep patient hypertensive euvolemia hypervolemia . A recently propose option dilate cerebral vessel infuse continuously another vasodilatory calcium channel blocker , nicardipine , support systemic blood pressure ( BP ) vasopressor constrict cerebral vasculature time . Nicardipine also use extensively intra-arterially bolus infusion dilate vasospastic cerebral vessel rescue therapy severe vasospasm . Clevidipine novel , short-acting calcium channel blocker , small series patient SAH Henry Ford Hospital , able control elevate BP efficiently within narrow window , without adverse event . It never use ameliorate vasospasm , theoretically offer advantage compare nicardipine due short half-life easy titratability . Except use clevidipine BP control investigator previous study , data clevidipine use SAH data effect drug vasospasm . In single-center , open-label , uncontrolled , pilot clinical study , investigator hypothesize clevidipine low-rate infusion decrease sonographically-detected moderate cerebral vasospasm aneurysmal SAH . The dose drug exploratory study 2.5 5 time low dose use previously control BP . The effect drug evaluate 20 patient TCD monitor 3 period : 1-hour pre-infusion , 4-hour infusion 4-hour post infusion . The cerebral blood flow velocity , surrogate marker vasospasm , compare 3 period . The primary efficacy end-point percentage measurement least 10 % decrease velocity infusion period . Potential long-term effect discontinuation drug also evaluate post-infusion 4-hour period beyond , last follow . The major safety issue hypotension induce drug period vasospasm present . For reason , two measure take . First , patient moderate vasospasm evaluate . Second , vasopressor use need infusion period counteract systemic circulatory effect drug maintain stable systemic Mean Arterial Pressure ( MAP ) within 10 % range compare pre-infusion . Potential effect cerebral vasodilation intracranial pressure ( ICP ) also evaluate infusion post-infusion period elevation &gt; 10 mm Hg report .</detailed_description>
	<mesh_term>Aneurysm</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Subarachnoid Hemorrhage</mesh_term>
	<mesh_term>Intracranial Aneurysm</mesh_term>
	<mesh_term>Vasospasm , Intracranial</mesh_term>
	<mesh_term>Clevidipine</mesh_term>
	<criteria>Age 1880 year Diagnosis SAH ( diagnose per history , neuroimaging lumbar puncture ) Presence secure aneurysm via clip coil Hunt Hess grade &lt; 5 ( nonsedated paralyzed patient ) Glasgow Coma scale &gt; 4 ( nonsedated paralyzed patient ) MAP goal set treat physician Temporal insonation window presence TCD Moderate supratentorial vasospasm per daily TCD ( CBFV 130180 cm/sec Lindergaard index 35 Middle Cerebral artery Internal Cerebral artery Anterior Cerebral artery ) Very young old patient ( &lt; 18 &gt; 80 year old ) Traumatic SAH ( aneurysm identify initial workup ) Perimesencephalic SAH also exclude Hunt Hess grade 5 ( deeply comatose brain dead patient ) Glasgow Coma scale 3 4 ( brain dead deeply comatose patient ) Patients mild severe supratentorial vasospasm ( CBFV &lt; 120 cm/sec Lindergaard index &lt; 3 &gt; 200 cm/sec Lindergaard index &gt; 6 , respectively , Middle Cerebral artery Internal Cerebral artery Anterior Cerebral artery ) Patients vasospasm posterior circulation ( CBFV &gt; 80 cm/sec Vertebral Basilar artery ) Patients severe tachycardia ( heart rate &gt; 110 ) Patients preexist leave bundle branch block permanent ventricular pacemaker Patients know allergy dihydropyridines include clevidipine allergic soybean , soy product , egg , egg product Patients defective lipid metabolism pathologic hyperlipemia lipoid nephrosis Patients acute pancreatitis , accompany hyperlipidemia Patients severe aortic stenosis Pregnant patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>subarachnoid hemorrhage</keyword>
	<keyword>aneurysm</keyword>
	<keyword>vasospasm</keyword>
	<keyword>clevidipine</keyword>
	<keyword>transcranial doppler</keyword>
</DOC>